BioSpace News Archive

MEI Pharma, Inc. issued the following statement in response to the disclosure made today by Anson Advisors Inc. and Cable Car Capital LLC.

Astellas Pharma Inc. announced positive topline results from the Phase 3b DAYLIGHT clinical trial for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms due to menopause.

Microba Life Sciences Limited announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease.

The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of RYSTIGGO (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Kalos Medical Inc. announced on June 23rd that South Korea’s Ministry of Food and Drug Safety designated the company’s DENEX hypertension treatment system as an Innovative Medical Device, a designation that recognizes medical devices that significantly improve safety and efficacy compared to existing medical devices and treatments.

Vernal Biosciences, an innovative mRNA and LNP Contract Development and Manufacturing Organization announced the completion of a $20MM funding round, led by Ampersand Capital Partners and Charles River Labs with participation from Dynamk Capital and the Vermont Center for Emerging Technologies.

Centene Corporation (NYSE: CNC) today announced that it will release its 2023 second quarter financial results at approximately 6 a.m. (Eastern Time) on Friday, July 28, 2023, and will host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results.